Overview:
NanoScale's focus in human health is on proprietary nanoplatform technologies for cancer diagnostics and imaging. The nanoplatforms for cancer were developed as a collaborative effort between NanoScale and Kansas State University. The company’s optical imaging agents are based on enzyme activated fluorescent cancer-targeting “stealth” iron/iron oxide core/shell nanoparticles for identification of tumor margins and in-vitro diagnostics.
Cancer Cases:
According to the American Cancer Society, there were approximately 11,714,000 people in the United States battling cancer in 2007. Not only does total financial cost of cancer exceed $228 billion, but we lose over 1,500 lives a day to cancer. NanoScale’s research on diagnosing cancer and advanced treatment could have a significant impact on these numbers and the lives of those around you.
Product Pipeline:
NanoScale is currently advancing two technologies. Learn more about NanoScale’s research on Optical Imaging and Diagnostics.
|
News:
- NanoScale Awarded Contract for Development of a Fluorescence Optical Imaging Technique for Breast Cancer. Learn More
Contracts and Funding:
- National Institutes of Health (NIH), Phase I and II SBIR ‘Functionalized Bimagnetic Core/Shell Fe/Fe3O4 Stealth Nanoparticles for Diagnosis & Treatment of Cancer’, Contracts #HHSN261200800059C, and # HHSN261201000111C
- National Science Foundation (NSF), Phase I and IB STTR ‘Intelligent Low Toxicity Materials for Cancer Diagnosis and Treatment’, Grant #IIP-0930673
- KBA (Matching funding for Phase I NIH and NSF)
- KBA Proof-of-Concept for Cancer Diangostics
Leadership:
- Bill Sanford, Chief Executive Officer, Founder of multi-billion dollar medical equipment company, Steris Corporation (View Bio)
- Stefan H. Bossmann, Ph.D., Professor, Kansas State University, 25 years of research experience in Chemistry and Chemical Engineering (Link)
Collaborators:
- Kansas State University:
- Stefan H. Bossmann, Ph.D., Professor of Chemistry (Link)
- Deryl Troyer, Ph.D., Professor of Anatomy and Physiology (Link)
- University of Kansas Medical Center:
- Scott Weir, PharmD, Ph.D., Director of the KUMC Institute for Advancing Medical Innovation, over 22 years of pharmaceutical industry experience (Link)
- Mark Cohen, MD, FACS, University of Kansas Cancer Center, Assistant Professor of Surgery, Pharmacology, Toxicology and Therapeutics (Link)
- Southeast Nebraska Cancer Center (Link)
- Beckloff Associates Inc. (Link)
Scientific Advisory Board:
- Adel A. F. Mahmoud, MD, Ph.D., Professor, Woodrow Wilson School and Molecular Biology, retired President of Merck Vaccines (Link)
- Esther Takeuchi, Ph.D., Professor, University at Buffalo, National Medal of Technology and Innovation Recipient, holds over 140 patents (Link)
- Trevor Jones, Chairman & Founder, ElectroSonics Medical, Inc. (Link)
|
